The increasing complexity of cancer chemotherapy now requires that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
BayJ.O., Ray-CoquardI., FayetteJ.. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer.2006; 119(3): 706–711.
2.
MakiR.G., WathenJ.K., PatelS.R.. Randomized phase ii study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol.2007; 25(19): 2755–2763.
3.
LeuK.M., OstruszkaL.J., ShewachD.. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol.2004; 22(9): 1706–1712.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology – Soft Tissue Sarcoma. V.3. 2007. http://www.nccn.org/. Accessed January 2, 2008.
7.
CohenM.R., SmetzerJ.Preparing for a damaging medication error. ISMP Medication Safety Alert!1999; June 2(4): No. 14.
8.
SavareseD., TaplinM.E., HalabiS., HarsV., KreisW., VogelzegangN.A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B trial 9780. Semin Oncol.1999; 26(5 suppl 17): 39–44.
9.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Antiemesis. V.1.2007. http://www.nccn.org/. Accessed November 20, 2007.
10.
KrisM.G., HeskethP.J., SomerfieldM.R.. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006;24(18): 2932–2947.
11.
Multinational Association for Supportive Care in Cancer. Antiemetic Guidelines. 2005. http://www.mascc.org/. Accessed November 20, 2007.
12.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
13.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
14.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
15.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
16.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
17.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
ZanottiK.M., MarkhamM.Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Safety.2001; 24(10): 767–779.
20.
SmithT.J., KhatcheressianJ., LymanG.H.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006;24(19): 3187–3205.
21.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology - Myeloid Growth Factors. V.1.2007. http://www.nccn.org/. Accessed November 20, 2007.
22.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
23.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75(3): 397–405.
24.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
25.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
26.
DelalogeS., LlombartA., Di PalmaM.. Gemcitabine in patients with solid tumors and renal impairment. Am J Clin Oncol.2004; 27(3): 289–293.
27.
FloydJ., MirzaI., SachsB., PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33(1): 50–67.
